A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model

Area of Science:

• Pharmacology
• Urology
• Endocrinology

Background:

• Adenosine is crucial for erection, regulating blood flow and intracavernosal pressure (ICP).
• A3 adenosine receptor (A3AR) allosteric modulators, like CF602, enhance adenosine's natural binding to A3AR.
• Diabetic erectile dysfunction (ED) is a significant clinical challenge often linked to vascular dysfunction.

Purpose of the Study:

• To investigate the efficacy of CF602 in resolving erectile dysfunction in a diabetic rat model.
• To assess the impact of CF602 on erectile function parameters, including ICP and mean arterial pressure (MAP).
• To evaluate the effects of CF602 on key histological and molecular markers associated with erectile function.

Main Methods:

• Diabetic erectile dysfunction was induced in rats using streptozotocin and confirmed via apomorphine testing.
• Erectile function was assessed by measuring ICP and MAP during cavernosal nerve electrostimulation.
• CF602 was administered topically or orally at various doses before functional assessment, followed by tissue analysis.

Main Results:

• Both topical and oral CF602 treatments demonstrated a significant, dose-dependent improvement in the ICP:MAP ratio.
• No significant changes in MAP were observed, indicating a specific effect on erectile function.
• CF602 administration led to increased ratios of smooth muscle to collagen, vascular endothelial growth factor, and endothelial nitric oxide synthase.

Conclusions:

• CF602 effectively improves erectile function in a diabetic rat model through both topical and oral administration.
• The observed improvements are associated with enhanced vascular and smooth muscle components crucial for erection.
• CF602 shows promise as a potential therapeutic agent for treating erectile dysfunction, warranting further clinical investigation.